About The Study: This cross-sectional study of privately insured patients found a more than 2-fold increase in use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as anti-obesity medications from 2022 to 2023, with a 25.6% decrease in the rate of metabolic bariatric surgery during the same period. Our results provide a national contemporaneous estimate of the decline in metabolic bariatric surgery associated with the era of GLP-1 RAs.
Corresponding Author: To contact the corresponding author, Thomas C. Tsai, MD, MPH, email ttsai@bwh.harvard.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2024.41380)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.41380?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=102524
About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
Journal
JAMA Network Open